Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 156

1.

Post-autologous transplant maintenance therapies in lymphoma: current state and future directions.

Riedell PA, Bishop MR.

Bone Marrow Transplant. 2017 Oct 2. doi: 10.1038/bmt.2017.196. [Epub ahead of print] Review.

PMID:
28967896
2.

Long-Term Outcome of Inflammatory Breast Cancer Compared to Non-Inflammatory Breast Cancer in the Setting of High-Dose Chemotherapy with Autologous Hematopoietic Cell Transplantation.

Cheng YC, Shi Y, Zhang MJ, Brazauskas R, Hemmer MT, Bishop MR, Nieto Y, Stadtmauer E, Ayash L, Gale RP, Lazarus H, Holmberg L, Lill M, Olsson RF, Wirk BM, Arora M, Hari P, Ueno N.

J Cancer. 2017 Mar 25;8(6):1009-1017. doi: 10.7150/jca.16870. eCollection 2017.

3.

PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation.

Godfrey J, Bishop MR, Syed S, Hyjek E, Kline J.

J Immunother Cancer. 2017 Feb 21;5:11. doi: 10.1186/s40425-017-0211-z. eCollection 2017.

4.

Emerging role of checkpoint blockade therapy in lymphoma.

Galanina N, Kline J, Bishop MR.

Ther Adv Hematol. 2017 Feb;8(2):81-90. doi: 10.1177/2040620716673787. Epub 2017 Jan 22. Review.

5.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.

Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV.

J Immunother Cancer. 2016 Dec 20;4:90. doi: 10.1186/s40425-016-0188-z. eCollection 2016.

6.

Mature T- and NK-cell non-Hodgkin lymphoma in children and young adolescents.

Pillai V, Tallarico M, Bishop MR, Lim MS.

Br J Haematol. 2016 May;173(4):573-81. doi: 10.1111/bjh.14044. Epub 2016 Mar 15. Review.

PMID:
26992145
7.

Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment.

D'Angelo CR, Kocherginsky M, Pisano J, Bishop MR, Godley LA, Kline J, Larson RA, Liu H, Odenike O, Stock W, Artz AS.

Leuk Lymphoma. 2016 Aug;57(8):1807-13. doi: 10.3109/10428194.2015.1113279. Epub 2015 Dec 24.

PMID:
26699199
8.

Update on checkpoint blockade therapy for lymphoma.

Kline J, Bishop MR.

J Immunother Cancer. 2015 Jul 21;3:33. doi: 10.1186/s40425-015-0079-8. eCollection 2015.

9.

High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses.

Mossoba ME, Halverson DC, Kurlander R, Schuver BB, Carpenter A, Hansen B, Steinberg SM, Ali SA, Tageja N, Hakim FT, Gea-Banacloche J, Sportes C, Hardy NM, Hickstein DD, Pavletic SZ, Khuu H, Sabatini M, Stroncek D, Levine BL, June CH, Mariotti J, Rixe O, Fojo AT, Bishop MR, Gress RE, Fowler DH.

Clin Cancer Res. 2015 Oct 1;21(19):4312-20. doi: 10.1158/1078-0432.CCR-15-0340. Epub 2015 Jun 12.

10.

Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients.

Yew PY, Alachkar H, Yamaguchi R, Kiyotani K, Fang H, Yap KL, Liu HT, Wickrema A, Artz A, van Besien K, Imoto S, Miyano S, Bishop MR, Stock W, Nakamura Y.

Bone Marrow Transplant. 2015 Sep;50(9):1227-34. doi: 10.1038/bmt.2015.133. Epub 2015 Jun 8.

11.

Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients.

Muffly LS, Kocherginsky M, Stock W, Chu Q, Bishop MR, Godley LA, Kline J, Liu H, Odenike OM, Larson RA, van Besien K, Artz AS.

Haematologica. 2014 Aug;99(8):1373-9. doi: 10.3324/haematol.2014.103655. Epub 2014 May 9.

12.

Symptom distress predicts long-term health and well-being in allogeneic stem cell transplantation survivors.

Bevans MF, Mitchell SA, Barrett JA, Bishop MR, Childs R, Fowler D, Krumlauf M, Prince P, Shelburne N, Wehrlen L, Yang L.

Biol Blood Marrow Transplant. 2014 Mar;20(3):387-95. doi: 10.1016/j.bbmt.2013.12.001. Epub 2013 Dec 17.

13.

Treatments of disease relapse after allogeneic stem cell transplantation focusing on donor lymphocyte infusion.

Liu HT, Liu DH, Huang XJ, Artz A, Bishop MR.

Chin Med J (Engl). 2013 Nov;126(22):4380-8. No abstract available.

PMID:
24238533
14.

Including unfamiliar stimuli in preference assessments for young children with autism.

Kenzer AL, Bishop MR, Wilke AE, Tarbox JR.

J Appl Behav Anal. 2013 Fall;46(3):689-94. doi: 10.1002/jaba.56. Epub 2013 Jul 10.

PMID:
24114234
15.

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.

Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, Hakim FT, Halverson DC, Fowler DH, Hardy NM, Mato AR, Hickstein DD, Gea-Banacloche JC, Pavletic SZ, Sportes C, Maric I, Feldman SA, Hansen BG, Wilder JS, Blacklock-Schuver B, Jena B, Bishop MR, Gress RE, Rosenberg SA.

Blood. 2013 Dec 12;122(25):4129-39. doi: 10.1182/blood-2013-08-519413. Epub 2013 Sep 20.

16.

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: introduction.

Wayne AS, Giralt S, Kröger N, Bishop MR.

Biol Blood Marrow Transplant. 2013 Nov;19(11):1534-6. doi: 10.1016/j.bbmt.2013.08.016. Epub 2013 Sep 10.

17.

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation.

Gress RE, Miller JS, Battiwalla M, Bishop MR, Giralt SA, Hardy NM, Kröger N, Wayne AS, Landau DA, Wu CJ.

Biol Blood Marrow Transplant. 2013 Nov;19(11):1537-45. doi: 10.1016/j.bbmt.2013.08.010. Epub 2013 Sep 6.

18.

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies.

Avigan D, Hari P, Battiwalla M, Bishop MR, Giralt SA, Hardy NM, Kröger N, Wayne AS, Hsu KC.

Biol Blood Marrow Transplant. 2013 Dec;19(12):1661-9. doi: 10.1016/j.bbmt.2013.08.011. Epub 2013 Sep 7.

19.

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation.

de Lima M, Porter DL, Battiwalla M, Bishop MR, Giralt SA, Hardy NM, Kröger N, Wayne AS, Schmid C.

Biol Blood Marrow Transplant. 2014 Jan;20(1):4-13. doi: 10.1016/j.bbmt.2013.08.012. Epub 2013 Sep 7.

20.

Host lymphocyte depletion as a strategy to facilitate early full donor chimerism after reduced-intensity allogeneic stem cell transplantation.

Salit RB, Fowler DH, Dean RM, Pavletic SZ, Hakim FT, Steinberg SM, Hardy NT, Sportes C, Gress RE, Bishop MR.

Biol Blood Marrow Transplant. 2013 Oct;19(10):1509-13. doi: 10.1016/j.bbmt.2013.08.001. Epub 2013 Aug 13.

Supplemental Content

Loading ...
Support Center